HSP-XX

HSP-XX is a preclinical-stage small molecule drug candidate being developed by Neuropeutics for the treatment of neurodegenerative diseases characterized by TDP-43 proteinopathy, including Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), and Alzheimer's disease. The compound is designed to target and inhibit the aggregation of TDP-43, a protein that misfolds and forms toxic clumps in the central nervous system of patients with these conditions. Although the specific molecular target is not fully disclosed, the "HSP" designation suggests a mechanism of action involving the modulation of Heat Shock Proteins (HSPs). These proteins function as molecular chaperones that maintain protein homeostasis by preventing or reversing the misfolding and accumulation of proteins like TDP-43.